Crohn Disease
📧 Sign up to get email alerts when something new happens for Crohn Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-04-15FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab submitted by Janssen Biotech, Inc. The action pertains to a supplemental submission …
-
EMA approval · 2026-03-30EMA Authorised: Imuldosa (ustekinumab) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Imuldosa (ustekinumab) from Accord Healthcare S.L.U. for Crohn's disease, psoriasis, and psoriatic …
-
EMA approval · 2026-03-30EMA Authorised: Uzpruvo (ustekinumab) — Stada Arzneimittel AG
EMA authorised Uzpruvo (ustekinumab) for the treatment of psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.
-
EMA approval · 2026-03-25EMA Authorised: Otulfi (ustekinumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Otulfi, a ustekinumab product from Fresenius Kabi Deutschland GmbH, for Crohn's disease and Ulcerative colitis.
-
EMA approval · 2026-03-19EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
EMA authorised Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, expanding treatment options in rheumatoid …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-03-06FDA Approved: SKYRIZI — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for SKYRIZI (risankizumab-rzaa) from AbbVie Inc. The action updates or expands the drug's regulatory…
-
EMA approval · 2026-03-03EMA Authorised: Entyvio (vedolizumab) — Takeda Pharma A/S
The European Medicines Agency authorised Entyvio (vedolizumab) for the treatment of ulcerative colitis and Crohn's disease, with Takeda Phar…
-
FDA approval · 2026-02-25FDA Approved: ENTYVIO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ENTYVIO (vedolizumab) submitted by Takeda Pharmaceuticals America, Inc., to support an expanded …
-
EMA approval · 2026-02-24EMA Authorised: Fymskina (ustekinumab) — Formycon AG
The EMA authorised Fymskina, an ustekinumab biosimilar from Formycon AG, for Crohn's disease, psoriasis, and psoriatic arthritis.
-
EMA approval · 2026-02-19EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
The EMA authorised Hulio, a biosimilar of adalimumab, for multiple inflammatory indications including hidradenitis suppurativa, psoriasis, u…
-
EMA approval · 2026-02-18EMA Authorised: Wezenla (ustekinumab) — Amgen Technology (Ireland) UC
EU authorization for Wezenla, a ustekinumab product from Amgen Technology (Ireland) UC, indicated for psoriasis, psoriatic arthritis, and Cr…
-
EMA approval · 2026-02-17EMA Authorised: Usrenty (ustekinumab) — Biosimilar Collaborations Ireland Limited
The EMA authorised Usrenty (ustekinumab biosimilar) by Biosimilar Collaborations Ireland Limited for Crohn's disease.
-
EMA approval · 2026-02-17EMA Authorised: Inflectra (infliximab) — Pfizer Europe MA EEIG
EMA authorised Inflectra (infliximab) as a biosimilar to Remicade for multiple inflammatory diseases including rheumatoid and psoriatic arth…
-
EMA approval · 2026-02-16EMA Authorised: Yesintek (ustekinumab) — Biosimilar Collaborations Ireland Limited
The European Medicines Agency authorised Yesintek, a biosimilar of ustekinumab, for use in psoriasis, psoriatic arthritis, and Crohn's disea…
-
EMA approval · 2026-02-05EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) as a biosimilar of adalimumab for several inflammatory and autoimmune diseases, including rheumatoid art…
-
EMA approval · 2026-02-04EMA Authorised: Imraldi (adalimumab) — Samsung Bioepis NL B.V.
EMA authorised Imraldi, a biosimilar adalimumab by Samsung Bioepis NL B.V., for multiple inflammatory diseases including ankylosing spondyli…
-
FDA approval · 2026-02-02FDA Approved: TYRUKO — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for TYRUKO (natalizumab-sztn) from Sandoz Inc, updating the regulatory file for this biosimilar unde…
-
EMA approval · 2026-01-28EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EMA authorised Hukyndra (adalimumab) from Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, psoriati…
-
EMA approval · 2026-01-27EMA Authorised: Cimzia (certolizumab pegol) — UCB Pharma
The European Medicines Agency authorised Cimzia (certolizumab pegol) for treatment of rheumatoid arthritis and other inflammatory diseases, …
-
EMA approval · 2026-01-19EMA Authorised: Skyrizi (risankizumab) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Skyrizi (risankizumab) for multiple indications. This expands its approved uses to psoriasis, psoriatic arthritis, ulcera…
-
EMA approval · 2026-01-09EMA Authorised: Usymro (ustekinumab) — Gedeon Richter Plc.
EMA authorised Usymro (ustekinumab) by Gedeon Richter for Crohn's disease, psoriasis, and psoriatic arthritis.
-
FDA approval · 2026-01-07FDA Approved: YESINTEK — Supplemental Application (Biocon Biologics Inc.)
The FDA approved a supplemental application for YESINTEK (ustekinumab) from Biocon Biologics Inc. The action relates to the ustekinumab bios…
-
EMA approval · 2025-12-15EMA Authorised: Remicade (infliximab) — Janssen Cilag International NV
The EMA has authorised Remicade (infliximab) for multiple inflammatory diseases under Janssen Cilag International NV as the marketing author…
-
EMA approval · 2025-12-11EMA Authorised: Hyrimoz (adalimumab) — Sandoz GmbH
EMA authorised Hyrimoz (adalimumab) by Sandoz GmbH as a biosimilar to Humira for multiple inflammatory diseases, including rheumatoid arthri…
-
FDA approval · 2025-12-01FDA Approved: SELARSDI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for SELARSDI (USTEKINUMAB-AEKN), a biosimilar to ustekinumab.